AFFISE
Affise , the global technology leader in partnerships management and automation, today announced a Series A funding round worth $8 million. This recent funding round, led by Leta Capital and TMT Investments, follows a period of impressive growth for the company. Founded in Vilnius, Lithuania in 2016, Affise has doubled its revenue every year and now employs over 120 professionals in six offices around the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210224005005/en/
“Affise has shown remarkable international growth, which we are happy to intensify even further with the investment round,” said Alexander Chachava, Managing partner at Leta Capital. “We can see that performance marketing becomes essential across many new channels which were difficult to measure until recently. The company empowers its clients with the real tools to boost the business, and we believe that Affise is going to become an industry-standard in performance marketing automation software.”
“The funding round will help the team focus on geographic expansion in regions where advertising, affiliate marketing and economy as a whole are growing, namely the States and Asian countries. With such a great team and product, we believe in success,” - commented Artyom Inyutin, Co-founder & Head of Investments, TMT Investments.
As the partnership marketing industry continues an impressive growth of 10%, every year, its 2021 value is estimated to reach $1.2B. Affise endeavours to utilize the funding to expand its product suite, providing marketers with a single platform to automate and scale partnerships. Following a tremendous success entering the Chinese market in 2019, Affise plans to increase its presence in North America, LatAm, and SEA, as well as cement its leadership in Europe, Israel and India.
“Partnerships management is becoming the vital component of the marketing technology stack, and Affise has established itself as a leader in this fast-growing category,” said Stanislau Litvinau, CEO and Co-Founder, Affise. “Our commitment to representing the marketers’ interests has gained the trust of the leading agencies and networks, and we see significant potential to capture additional opportunity in the market. One strategy we’re aiming to complete with this funding is entering the adjacent market of direct advertisers and brands, empowering them to grow their marketing channel with affiliate programs”.
Affise works with over 1,000 customers, including leading brands and agencies such as Wargaming, Xapads, Hypercentage, Kismia, Mobavenue, Zorka.Mobi, Mobligent. The company boasts connections to a conglomerate of over 300,000 partners, which accelerates business growth. The winner of 14 awards in the last year alone, Affise has been crowned the leader in three categories by G2: Partner Management, Marketing Analytics, and Digital Analytics.
“The market evolution from traditional affiliates to new performance channels (influencers, brand-to-brand and other), along with the skyrocketing growth in e-Commerce in 2020, will encourage more small and medium advertisers to launch their affiliate programs'' - Dmitrii Zotov, CTO and Co-Founder, Affise. “This trend will generate demand for technological solutions to start and manage affiliate programs from scratch and achieve incremental growth. Thus, this funding round will enable us to follow Affise’s mission of empowering marketers with the tools needed to catapult their success and make accurate strategic decisions. This will drive innovations and transparency across the industry”.
About Affise
Affise is a partnership marketing platform for brands, advertisers and agencies to automate and scale their partner relations via all possible performance marketing channels: traditional affiliates, influencers, networks and agencies. The synergy of technology and the long standing experience allows Affise’s clients to make partnerships manageable and revenue predictable marketing channel. To learn more, visit www.affise.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210224005005/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AmTrust Financial Services and Blackstone Credit & Insurance Close Strategic Transaction and Launch Newly Formed Multinational MGACompany Named ANV Group Holdings Ltd.5.12.2025 13:00:00 CET | Press release
Strategic Transaction Unlocks Value for AmTrust and Positions ANV Group Holdings for Accelerated GrowthFormer AmTrust President Adam Karkowsky Leading ANV Group Holdings as Chairman and CEO AmTrust Financial Services, Inc. (“AmTrust” or the “Company”), a global specialty property casualty insurer, and Blackstone Credit & Insurance (“BXCI”), today announced the closing of a strategic transaction under which AmTrust and funds managed by BXCI have partnered to spin-off certain of AmTrust’s Managing General Agencies (“MGAs”) and fee-based businesses in the U.S., United Kingdom, and Continental Europe, into ANV Group Holdings Ltd. (“ANV”), a newly formed independent company, following receipt of regulatory approvals. AmTrust and ANV have entered into a ten-year capacity agreement through which AmTrust will remain the underwriter for the existing books of business offered through the MGAs. As previously announced on September 15, 2025, the agreement includes seven AmTrust subsidiaries: ANV S
Galderma Opens up New Chapter for Sculptra® with MDR Certification and New Expanded Indication for Body5.12.2025 07:00:00 CET | Press release
Sculptra®, the first proven regenerative biostimulator, has received European Union (EU) Medical Device Regulation (MDR) certification, expanding its current clinical application for the face to include gluteal area, posterior thighs, décolletage, and upper arms1 Studies investigating the efficacy of Sculptra on areas beyond the face show patients experienced progressive improvements in skin quality (including the improvement in cellulite appearance), firmness, lift, projection, and contour Sculptra’s versatility and new indication allow practitioners to shift patient treatment goals beyond rejuvenation toward enhancement, meeting evolving patient needs The certification validates Sculptra’s safety performance, efficacy, and quality, reinforcing Galderma’s commitment to innovation and meeting evolving patient needs Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the certification of Sculptra for body indications in the European Union (EU) following its
Northern Escape Heli-Skiing Takes the Title of “World’s Best Heli-Ski-Operator” for the 4th Year Running5.12.2025 02:40:00 CET | Press release
4x World’s Best Heli-Skiing Operation near Terrace, BC Northern Escape Heli-Skiing (NEH) has been named World’s Best Heli-Ski Operator 2025 by the World Ski Awards, marking its fourth straight victory following years 2022, 2023 and 2024. This recognition places NEH amongst an elite group of ski tourism operators consistently voted best in the world by industry leaders and enthusiasts alike. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251204074550/en/ A four-year run built on reliability NEH operates in British Columbia’s Skeena Mountains, where deep northern snow and vast terrain come together with small-group heli-skiing and heli snowboarding. When helicopters can’t safely fly, NEH has cat skiing readily available as a backup — an exceedingly rare offering in this industry. The operation spans over 833,571 wild acres of alpine bowls, glaciers and old-growth tree skiing. The NEH experience Guests choose from three lodge f
IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance5.12.2025 01:00:00 CET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), announced that its partner IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision oncology company, has received the clearance of an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 1 clinical trial of IDE034, a potential first-in-class B7H3/PTK7 bispecific antibody-drug conjugate (ADC). IDEAYA expects to begin patient enrollment in Q1 2026, initially evaluating patients with solid tumors known to express B7H3 and PTK7, including lung, colorectal, head and neck, and ovarian/gynecological cancers. IDE034 is a bispecific B7H3/PTK7 TOP1 ADC, independently developed by Biocytogen and licensed to IDEAYA in July 2024. The IND clearance marks an important milestone for this licensed program, supporting subsequent clinical development of IDE034, while highlighting Biocytogen’s technical capabilities in bispecific ADC discovery and development. Dr. Yue
Helical Fusion, Developer of Next-Generation Clean Energy Through Nuclear Fusion, Completes USD 5.5M Series A Extension Round5.12.2025 01:00:00 CET | Press release
Stakeholder base expands with participation from an individual-investor-oriented fund, alongside corporate and individual investors, bringing Total Funding to USD 38M Helical Fusion Co., Ltd. (Head Office: Chuo-ku, Tokyo; CEO: Takaya Taguchi; hereafter “Helical Fusion”), which is developing a next-generation energy source using Japan’s original Helical Stellarator technology to realize commercially viable fusion power plant in the 2030s, announced the completion of its Series A Extension round, raising approximately USD 5.5 million (≈ JPY 870 million). The round included investments from “Ecrowd NEXT”, a fund designed for individual investors, as well as multiple corporate investors and individual investors. As a result, Helical Fusion’s total Series A funding, including loans, amounts to approximately USD 21 million (≈ JPY 3.2 billion), bringing the company’s cumulative fundraising—including grants and loans—to approximately USD 38 million (≈ JPY 6.0 billion). With this funding, Helic
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom